Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    2(50%)
    Results Posted
    200%(2 trials)
    Terminated
    1(25%)

    Phase Distribution

    Phase 2
    1
    25%
    Phase 3
    3
    75%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    3

    Late Stage

    Phase Distribution4 total trials
    Phase 2Efficacy & side effects
    1(25.0%)
    Phase 3Large-scale testing
    3(75.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Active(2)
    Completed(1)
    Terminated(1)

    Detailed Status

    Recruiting1
    Terminated1
    Enrolling by invitation1
    Completed1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    2
    Success Rate
    50.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (25.0%)
    Phase 33 (75.0%)

    Trials by Status

    recruiting125%
    terminated125%
    enrolling_by_invitation125%
    completed125%

    Recent Activity

    2 active trials
    Showing 4 of 4
    recruitingphase_3

    Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

    NCT07396480
    enrolling_by_invitationphase_3

    Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

    NCT05674539
    terminatedphase_3

    Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

    NCT01339910
    completedphase_2

    Allogeneic Transplant in HIV Patients (BMT CTN 0903)

    NCT01410344

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT07396480Phase 3

    Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

    Recruiting
    NCT05674539Phase 3

    Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Enrolling By Invitation
    NCT01339910Phase 3

    Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

    Terminated
    NCT01410344Phase 2

    Allogeneic Transplant in HIV Patients (BMT CTN 0903)

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    4